Glenmark Pharmaceuticals Ltd., a research-driven global pharmaceutical company, has officially launched TEVIMBRA® (tislelizumab) in India, following approval from the Central Drugs Standard Control Organisation (CDSCO). This development marks Glenmark’s strategic entry into the country’s rapidly evolving immuno-oncology segment.

TEVIMBRA, an anti-PD-1 monoclonal antibody originally developed by BeiGene (now BeOne Medicines), is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)—either in combination with chemotherapy (as a first-line therapy) or as a standalone treatment (in second-line settings). It is also approved for use in oesophageal squamous cell carcinoma (ESCC), a condition particularly prevalent in India.

With this launch, Glenmark aims to widen access to globally benchmarked immunotherapies for Indian oncologists and patients. TEVIMBRA has already received approvals across major global markets, including the US, EU, China, and Australia, and has demonstrated consistent safety and efficacy across various solid tumour indications in pivotal Phase 3 clinical studies.

“The launch of TEVIMBRA represents a transformative moment in our oncology strategy,” said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd. “As cancer cases rise in India, we are committed to delivering advanced, research-based therapies that improve treatment outcomes and enhance patient quality of life.”

Addressing a Critical Disease Burden

NSCLC constitutes over 80% of lung cancer cases globally, with a significant incidence in India. Similarly, ESCC remains the predominant subtype of oesophageal cancer in the region. TEVIMBRA offers a targeted and differentiated therapeutic approach designed to restore T-cell function without causing widespread immune suppression.

Glenmark’s entry into immuno-oncology adds significant depth to its speciality portfolio, especially in a market where demand for precision medicine and novel therapies is steadily increasing.

Scientific Rigour Backed by Global Data

TEVIMBRA is a humanised IgG4 anti-PD-1 monoclonal antibody engineered to reduce binding to Fcγ receptors on macrophages. This allows for enhanced tumour targeting while minimising immune-related adverse events. The drug has been studied in over 70 clinical trials worldwide, involving nearly 14,000 patients and has already benefited more than 1.5 million patients globally.

Read more: Zeno Health Expands Footprint in Maharashtra with 75 New Stores, Creating 500+ Pharmacist Jobs and Enhancing Affordable Medicine Access

Strengthening India’s Oncology Ecosystem

This launch aligns with Glenmark’s broader mission to invest in innovative therapies across critical disease areas. With 11 manufacturing facilities across four continents and a presence in 80+ countries, Glenmark continues to bridge treatment gaps in complex diseases.

As part of its sustainability and access goals, the company’s focus on oncology is backed by strategic collaborations, R&D investments, and commitments to global best practices. Glenmark’s recognition by SBTi for climate goals further reinforces its status as a responsible industry leader. 

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!